Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL200 in Severe Sickle Cell Disease
NCT04091737Phase 1Terminated
- Sponsor
- CSL Limited
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CSL200 in sickle cell disease (SCD), sponsored by CSL Limited. Primary endpoints: Number of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) at 48 weeks and Number of subjects experiencing AEs, SAEs, and AESIs at 48 weeks. Started Oct 2019; status: terminated.
02
Drugs
CSL200
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04091737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091737.